MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

Search

Viatris Inc

Chiusa

SettoreSettore sanitario

9.29 0.43

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

9.25

Massimo

9.3

Metriche Chiave

By Trading Economics

Entrata

-2.5B

-3B

Vendite

-274M

3.3B

EPS

0.5

Rendimento da dividendi

5.38

Margine di Profitto

-93.476

Dipendenti

32,000

EBITDA

-2.7B

-2.3B

Raccomandazioni

By TipRanks

Raccomandazioni

Vendi

Previsioni per 12 mesi

-3.43% downside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

5.38%

2.40%

Utili prossimi

7 ago 2025

Prossima data del Dividendo

12 set 2025

Prossima data del' Ex Dividendo

22 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

633M

10B

Apertura precedente

8.86

Chiusura precedente

9.29

Notizie sul Sentiment di mercato

By Acuity

62%

38%

314 / 375 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Viatris Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

5 lug 2025, 04:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

4 lug 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

4 lug 2025, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

4 lug 2025, 20:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

4 lug 2025, 20:50 UTC

Discorsi di Mercato

Energy & Utilities Roundup: Market Talk

4 lug 2025, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

4 lug 2025, 16:20 UTC

Discorsi di Mercato

Energy & Utilities Roundup: Market Talk

4 lug 2025, 16:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

4 lug 2025, 16:20 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

4 lug 2025, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

4 lug 2025, 15:57 UTC

Discorsi di Mercato

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

4 lug 2025, 15:49 UTC

Discorsi di Mercato

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

4 lug 2025, 15:49 UTC

Acquisizioni, Fusioni, Takeovers

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

4 lug 2025, 15:49 UTC

Acquisizioni, Fusioni, Takeovers

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

4 lug 2025, 15:49 UTC

Acquisizioni, Fusioni, Takeovers

Credit Agricole Received All Required Authorizations

4 lug 2025, 15:48 UTC

Acquisizioni, Fusioni, Takeovers

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

4 lug 2025, 15:47 UTC

Acquisizioni, Fusioni, Takeovers

Credit Agricole: Agreement Was Announced on Dec. 19

4 lug 2025, 15:47 UTC

Acquisizioni, Fusioni, Takeovers

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

4 lug 2025, 15:46 UTC

Acquisizioni, Fusioni, Takeovers

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

4 lug 2025, 14:30 UTC

Acquisizioni, Fusioni, Takeovers

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

4 lug 2025, 13:53 UTC

Discorsi di Mercato

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

4 lug 2025, 13:41 UTC

Discorsi di Mercato

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

4 lug 2025, 13:41 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

4 lug 2025, 13:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

4 lug 2025, 12:37 UTC

Discorsi di Mercato

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

4 lug 2025, 12:37 UTC

Discorsi di Mercato

Fund Manager Roundup: U.S. Treasurys in Focus -2-

4 lug 2025, 12:30 UTC

Discorsi di Mercato

Fund Manager Roundup: U.S. Tariff Deadline Key for Dollar Outlook, U.K. Fiscal Risks In Focus for Pound

4 lug 2025, 12:15 UTC

Discorsi di Mercato

Targeted Tariffs Would Likely Support Dollar -- Market Talk

4 lug 2025, 12:13 UTC

Discorsi di Mercato

Further Pause in Tariffs Would Have Unclear Impact on Dollar -- Market Talk

4 lug 2025, 12:02 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Viatris Inc Previsione

Obiettivo di Prezzo

By TipRanks

-3.43% in calo

Previsioni per 12 mesi

Media 9 USD  -3.43%

Alto 10 USD

Basso 8 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Viatris Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Vendi

3 ratings

0

Acquista

2

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

8.48 / N/ASupporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Very Strong Bullish Evidence

A lungo termine

Strong Bearish Evidence

Sentiment

By Acuity

314 / 375 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Viatris Inc

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.